Abstract It has been a little more than 20 years since the first appreciation that the biologically active hormonal form of the secosteroid vitamin D-classically categorized as a regulator of calcium/phosphorous metabolism and bone mineralization-can exert effects on cells of the immune system. Since then a substantial literature has accumulated to suggest that these effects are exerted on multiple immune cell types, are predominantly suppressive at pharmacologic levels, and are potent enough to have true therapeutic potential in the management or prevention of immune-mediated diseases. Less clear at present, however, are the physiological roles played by the vitamin D endocrine system in the regulation of normal and abnormal immune responses. In this review, an appraisal of the current understanding of vitamin D-mediated immune regulation is presented that emphasizes progress towards its clinical application as well as the manner in which emerging models of normal immune function may facilitate a more complete understanding of its physiologic significance.
prevention of self-destructive responses. A model of immune regulation is presented in Figure 1 that incorporates a number of emerging concepts and will serve as a template for discussing current understanding of the physiologic and therapeutic importance of vitamin D-mediated effects on the vertebrate immune system. Central to this model is the role of the DC (7, 49, 58, 90, 122) . Dendritic cells have been shown to process protein antigens from invading microorganisms as well as from apoptotic or necrotic cells within peripheral tissues and to present these as major histocompatibility complex (MHC)/peptide complexes to T-cells in the spleen and lymph nodes (90) . The outcome of antigen presentation by DCs is variable and is strongly dependent on the presence or absence of signals derived from the innate immune response (7, 49) . Thus, self-antigen derived from apoptotic cells in the absence of innate signals may preferentially generate regulatory T-cells that actively suppress autoimmunity (58, 122) . In contrast, antigen derived directly from invading microorganisms or from infected cells will be accompanied by an array of innate signals that instruct the DC to potently activate antigen-specific Tand B-cells (7, 49) . Patterned T-cell responses (Th-1 and Th-2) are further selected for by antigen-bearing DCs through the secretion of modifying cytokines such as IL-12 (71) . According to this model, therefore, both immune tolerance to self and immune activation against invading organisms are the result of similar antigen trafficking processes but differ in the context in which antigen is encountered. At all levels this cross-communication between the innate and cognate arms of the immune system is subject to positive and negative regulatory influences that may be tissue-specific or genetically variable. Furthermore, manipulations of innate/cognate interactions are likely to be of specific benefit in the prevention or treatment of diseases in which immune responses are deficient or maladaptive.
INITIAL OBSERVATIONS OF VITAMIN D IMMUNE EFFECTS The Presence of Vitamin D Receptors in Cells of the Immune System
The first indication that receptors for the active form of vitamin D [1α,25-dihydroxycholecalciferol, subsequently referred to as 1,25(OH) 2 D 3 ] are present in immune cells came from the observation of prodifferentiative effects of 1,25(OH) 2 D 3 on murine myelomonocytic cell lines (1, 11, 60) and from biochemical studies demonstrating a vitamin D receptor (VDR) in human thymus and peripheral blood leukocytes (15, 104, 111) . Subsequently, multiple authors were able to confirm that the VDR is constitutively expressed in significant amounts by human and murine monocytes and is inducibly expressed to similar levels in lymphocytes following delivery of activation signals (15, 82, 83, 102, 105) . In lymphocyte-rich tissues such as tonsil and thymus, expression of VDR was confined to cells in the early stages of activation and mitogenesis (103, 107) . As characterization of T-cell signaling requirements and subtypes improved, it was additionally shown that VDR expression levels were highest following strong activation signals through the Tcell receptor (TCR) and accessory receptors (141) and were comparable in helper (CD4+) and cytotoxic (CD8+) subsets (102, 132) .
Immune Consequences of Vitamin D Deficiency
In parallel with observations on VDR expression in immune cell subtypes, a smaller number of reports emerged suggesting immune defects in vitamin D-deficient patients and experimental animals (51) . Most notably, studies by Bar-Shavit et al. (10) and Toss et al. (126) provided evidence for defects in macrophage proinflammatory function and in localized antigen-specific cellular immune responses [delayed-type hypersensitivity (DTH)] during vitamin D deficiency. More recently, Yang et al. (139) have definitively demonstrated reduced DTH responses in profoundly vitamin D-deficient mice. These findings, while consistent with a longstanding view that individuals with rickets are abnormally prone to infection (51) , are paradoxical in the context of the abundant literature (reviewed in the following sections) supporting an immunosuppressive role for 1,25(OH) 2 D 3 and related analogs. Nonetheless, as subsequently discussed, a balanced model of the immunoregulatory effects of vitamin D must incorporate evidence that, under physiological conditions, 1,25(OH) 2 D 3 may function to facilitate rather than inhibit elements of the normal immune response.
THE EFFECTS OF VITAMIN D ON INDIVIDUAL IMMUNE CELL TYPES

Monocytes, Macrophages, and Dendritic Cells
At the time that receptors for 1,25(OH) 2 D 3 were identified in monocytes and myelomonocytic cell lines the monocyte was primarily viewed as a precursor form of the tissue macrophage-a phagocytic cell capable of secreting an array of proinflammatory products and intimately involved in host defense against bacterial infection. A number of studies demonstrated that 1,25(OH) 2 D 3 induced differentiation of monocytes and monocyte-derived cell lines toward a macrophage-like phenotype (11, 60, 101, 114, 137) . Furthermore, investigations of patients with granulomatous conditions (sarcoidosis and tuberculosis) by Adams's and others' groups demonstrated the generation of 1,25(OH) 2 D 3 by disease-associated macrophages (4, 5, 8, 26) . In contrast to hydroxylase regulation in the kidney, 25-hydroxyvitamin D 3 1α-hydroxylase activation in macrophages was not associated with induction of 25-hydroxyvitamin D 3 24-hydroxylase activity (4)-a phenomenon subsequently shown by Dusso et al. to be mediated by interferon-γ (47) . The expression of 25-hydroxyvitamin D 3 1α-hydroxylase by macrophages has been formally confirmed by Overbergh et al. (96) and shown to be induced by activating stimuli (interferon-γ and LPS) or by viral infection (94, 96) .
Combined with observations of increased infections and reduced capacity to mount inflammatory responses in the setting of vitamin D deficiency, these findings suggest a paracrine role for 1,25(OH) 2 D 3 in promoting localized macrophagedependent inflammation (4, 8, 26, 94, 114) . In keeping with this model, pleural fluid from patients with tuberculous pneumonia was found to contain high concentrations of 1,25(OH) 2 D 3 (8) . Studies of the antigen presentation function of monocytes yielded, however, qualitatively different results. A series of reports by Rigby et al. (117) , Tsoukas et al. (128) , and Xu et al. (137) demonstrated that monocytes exposed to 1,25(OH) 2 D 3 in culture have significant reductions in class II MHC expression and in T-cell stimulatory capacity. In addition, it was recognized that the ability to provide the accessory ("co-stimulatory") signals necessary for T-cell activation was also potently inhibited in 1,25(OH) 2 D 3 -treated monocytes (116, 137) .
A clearer understanding of these latter observations has been permitted by progress in two key areas of immunology: (a) the characterization of the specific co-stimulatory receptors expressed by antigen presenting cells (APCs), including CD80 (B7-1), CD86 (B7-2), and CD40; and (b) the identification of a specialized subtype of APC, also derived from monocytes, termed dendritic cells (DCs). Dendritic cells are now appreciated as the primary initiators of T-cellmediated immune responses in vivo and, when fully mature, express high levels of class II MHC, CD80, CD86, CD40, and an array of other accessory ligands and immunostimulatory products (7, 90) . Dendritic cells are present within essentially all organs and demonstrate migratory patterns that allow for the uptake and trafficking of disease-associated antigens from peripheral tissues to specialized lymphoid organs where cellular immune responses are initiated. The process by which DCs pass from low to high T-cell stimulatory capacity is termed "maturation" (7, 49, 90) . Because inappropriate DC maturation may result in excessive or unnecessary T-cell-mediated immune responses (autoimmunity), this process is subject to multiple positive and negative regulatory influences. In addition, an active role for immature DCs in promotion of immune tolerance to self or nonthreatening foreign antigens (such as gut flora or food components) has also been identified (58, 122) . It is of considerable interest, therefore, that 1,25(OH) 2 D 3 has recently been shown by a number of groups to potently inhibit DC maturation by a VDR-dependent mechanism (13, 25, 27, 54, 55, 99, 100, 120, 130) . These studies have been primarily carried out using DCs generated in culture from human monocytes or murine bone marrow-derived precursors and have demonstrated significant reductions in DC surface expression of class II MHC, co-stimulatory ligands (CD80, CD86, CD40), and other maturation-induced proteins (CD1a, CD83). An example of dose-dependent inhibition of DC maturation by a 1,25(OH) 2 D 3 -derived analog is illustrated in Figure 2 . This figure further demonstrates that the yield of DCs from bone marrow culture is potently inhibited by higher concentrations of 1,25(OH) 2 D 3 analog than those associated with impaired maturation (10 −8 to 10 −9 M versus 10 −10 to 10 −12 M). Secretion of the immunostimulatory cytokine IL-12 is also reduced in DCs generated in the presence of 1,25(OH) 2 D 3 while, in some but not all of these studies, DC secretion of the potentially immunosuppressive cytokine IL-10 was increased (99, 130) . Functionally, the capacity of ) and the co-stimulatory proteins CD80 and CD86. Results for these two markers of DC maturation are expressed as MFI of cells expressing the DC-specific cell surface protein CD11c (mean ± SD of triplicate wells for each concentration). Dose-dependent inhibition occurred up to 10 −10 M D 3 analog. At concentrations greater than 10 −10 M, DC surface levels of class II MHC and CD80/CD86 increased but significant inhibition of DC yield occurred (insert graph-total CD11c +ve cells per well shown as mean ± SD of triplicate wells for each concentration) revealing an inhibitory effect on the DC differentiation process at these high concentrations. * = p < 0.05 for values lower than corresponding results for cells not exposed to D 3 analog. Abbreviations: DC, dendritic cell; MHC, major histocompatibility complex; MFI, mean fluorescence intensity; SD, standard deviation. 
T Lymphocytes
Direct inhibitory effects of 1,25(OH) 2 D 3 on T-cells have also been convincingly demonstrated although their physiologic and therapeutic importance relative to APC inhibition continues to be a source of conjecture. An extensive series of publications between 1984 and 1990 by the groups of Krane, Rigby, Manolagas, Lemire, and others established a basic profile for these effects (16, 17, 68, 81, 82, 112, 115, 118, 127) . This included evidence that antigen-or lectin-stimulated human and murine T-cell proliferation, IL-2 secretion, and cell cycle progression from G 1a to G 1b are inhibited in vitro by concentrations of 1,25 (OH) 2 D 3 between 10 −12 and 10 −8 M. The reported magnitude of this inhibition was quite variable and, in most studies, could be partially or completely overcome by IL-2 supplementation or application of more potent stimuli. Clarification of direct T-cell inhibition was provided by studies of highly purified T-cells and T-cell clones (70, 72, 76, 131) . Although inhibition of IL-2 production has been repeatedly confirmed as a central mechanism for 1,25(OH) 2 D 3 -mediated T-cell inhibition, more recent studies have also demonstrated IL-2-independent attenuation of interferon gamma (IFNγ ), GM-CSF, and, perhaps, IL-4 production by T-cells (110, 113, 125) . Despite the expression of VDR at comparable levels in both helper (CD4+) and cytotoxic (CD8+) T-cell subsets (102, 132) , it has been repeatedly observed that CD4+ Tcells are the preferential target of 1,25(OH) 2 D 3 -mediated inhibition during primary activation in vitro (73, 102, 131) . Whether this preferential targeting of CD4+ Tcells also occurs in vivo or during secondary ("memory") activation of T-cells remains to be determined, although Meehan Figure 1 ) and is a self-perpetuating process in that one subtype inhibits the generation of the other (71) . The influence of 1,25(OH) 2 D 3 on T-helper polarization has been the topic of a number of recent reports (19, 64, 76, 121) . Although some conflicting results have been presented, a balanced appraisal of the data from these studies suggests three specific conclusions: (a) the primary generation of Th-1-type T-cell responses is potently inhibited by 1,25(OH) 2 D 3 both in vitro and in vivo, (b) for T-cell activation occurring under conditions that are not strongly polarizing, the presence of supraphysiological concentrations of 1,25(OH) 2 D 3 will favor the emergence of a predominant Th-2 phenotype, (c) production of IFNγ by previously activated T-cells is more potently inhibited than production of IL-4. Thus, while 1,25(OH) 2 D 3 does not directly up-regulate IL-4 and may, in fact, have modest inhibitory effects on the IL-4 promoter in naïve T-cells (121) , its influence over T-helper polarization is likely to favor the Th-2 phenotype, particularly after repeated stimulations. In support of this conclusion, mice protected from EAE, murine lupus, and autoimmune diabetes by administration of 1,25(OH) 2 D 3 have evidence of Th-2 polarization in vivo (34, 46, 97) .
A separate and provocative possibility-that 1,25(OH) 2 D 3 may promote the generation of regulatory T-cells (T reg )-has also been raised (52, 53, 88) . The characteristic features of T reg , as defined by a burgeoning literature, include the combined expression of CD4 and CD25, the secretion of potentially inhibitory cytokines (IL-10 and TFG-β), and the ability to potently inhibit antigen-specific T-cell activation (40) . The fact that T reg have been reported by different groups to mediate inhibition by both contact-dependent and noncontact-dependent mechanisms suggests that more than one population of such cells exists (40) . In a murine islet cell transplant model, Gregori et al. (52) found that the combination of 1,25(OH) 2 D 3 and the immunosuppressant drug mycophenolate mofetil not only protected against graft rejection, but increased the proportion of CD4+CD25+ Tcells in regional lymph nodes. Furthermore, transfer of these cells to untreated animals resulted in protection from rejection-a characteristic feature of T reg (52) . Similar observations have been made by the same group in a model of autoimmune diabetes (53) . In this model, treatment with a 1,25(OH) 2 D 3 analog alone was sufficient to enhance protective T reg activity. The authors speculate that the promotion of T reg by 1,25(OH) 2 D 3 represents the indirect result of DC modulation rather than a direct T-cell effect. In an APC-free in vitro system, however, Barrat et al. (9) demonstrated that repeated stimulation of CD4+ T-cells in the presence of 1,25(OH) 2 D 3 and a corticosteroid (dexamethasone) resulted in a homogenous population of cells with predominant IL-10 production and the ability to suppress autoimmune demyelination in vivo in an antigen-specific manner. Thus, although the role of 1,25(OH) 2 D 3 in the normal generation and maintenance of T reg and the promotion of self-tolerance remains speculative, the combination of 1,25(OH) 2 D 3 agonists with additional immunomodulatory agents (as expanded upon below) may hold specific promise in this regard.
B Lymphocytes and NK Cells
The influence of 1,25(OH) 2 (41, 62, 67, 74, 138) . In most of these experiments it was not possible to distinguish between indirect effects on T-cell help and a direct effect on B-cells. In one report by Provvedini et al. (105) , however, T-cell-independent inhibition of stimulated immunoglobulin production by Epstein Barr Virus-transformed human B-cells was shown. In this same study, expression of receptor for 1,25(OH) 2 D 3 by the transformed B-cells was detected raising the possibility that B-cells may be induced to respond to 1,25(OH) 2 D 3 , under specific circumstances. Finally, in an in vivo study, Abe et al. (3) described an enhancement of antisheep erythrocyte antibody production following treatment with a low dose of a 1,25(OH) 2 D 3 analog. Based on this scant literature it is difficult at present to estimate the potential for 1,25(OH) 2 D 3 agonists to modify antibodymediated disease processes. For NK cells, a lymphocyte subset involved in lysis of disease-associated cells that demonstrate altered expression of class I MHC and other normal surface proteins, even less information is available regarding the effect, if any, of 1,25(OH) 2 D 3 . In a single report, the generation of "NK activity" in human peripheral blood mononuclear cell cultures was attenuated by addition of 1,25(OH) 2 D 3 but the cytotoxicity of NK cells was not directly inhibited (91) . Thus, there is currently no convincing evidence for a direct interaction between this cell type and the vitamin D system.
VITAMIN D-MEDIATED MODULATION OF INTRACELLULAR SIGNALING IN IMMUNE CELLS
Activation events in lymphocytes and APC populations are the result of altered gene expression patterns that are orchestrated by an array of intracellular signaling pathways. The signaling mechanisms operational in lymphocytes and APCs are, in some cases, unique to cells of the immune system but, in the majority, are shared by many cell types. The mechanism of action of most immunomodulatory agents can be linked to discrete effects on one or more such pathways. Although the primary mechanism of action of 1,25(OH) 2 D 3 is to directly regulate the transcription of individual genes by forming a DNA-binding complex with the VDR and other associated proteins (35, 66) , there is abundant evidence that many of its effects on cellular function result indirectly from modulation of intracellular signaling pathways. Although it is beyond the scope of this review to document in detail the reported signaling modifications that have been ascribed to 1,25(OH) 2 D 3 , there have been a variety of studies demonstrating potent effects of 1,25(OH) 2 D 3 on some of the signaling pathways that are integral to the regulation of antigen presentation and lymphocyte activation (6, 42, 45, 59, 84, 123, 136, 140) . These findings are summarized in Table 1 . An example of 1,25(OH) 2 D 3 -mediated modulation of a key intracellular signaling pathway involved in immune function (the NF-κB pathway) is provided in Figure 3 . In this experiment an additive effect of the combination of a 1,25(OH) 2 D 3 agonist and a corticosteroid is also shown. The NF-κB pathway consists of a number of related proteins that regulate gene expression when translocated to the nucleus as hetero-or homodimers and is central to differentiation, maturation, activation, and survival of APCs, from five or six weeks of age demonstrated partial reversal of autoimmunity in treated animals with reduced lymphoproliferation, nephritis, arthritis and prolonged survival but no effect on production of autoantibodies. Lemire examined the effects of a nonhypercalcemic dose of 1,25(OH) 2 D 3 on MRL lpr/lpr mice and noted improvement in nephritis and skin lesions but not generalized lymphoproliferation (79) . Together these studies suggest a partial beneficial effect of 1,25(OH) 2 D 3 agonists on SLElike disease when initiated prior to the onset of clinical manifestations.
THE EFFECTS OF VITAMIN D THERAPY ON EXPERIMENTAL MODELS OF IMMUNE-MEDIATED DISEASE
A second model in which the therapeutic and mechanistic effects of 1,25(OH) 2 D 3 have been extensively studied is the nonobese diabetic (NOD) mouse, a strain in which multiple genetic polymorphisms lead to a high incidence of autoimmune diabetes mellitus (135) . In this model, many of the immune phenomena that have been observed are similar to those that have been characterized in human type I diabetes mellitus (135) . The group of Mathieu and Bouillon and colleagues have clearly shown that treatment of NOD mice with 1,25(OH) 2 D 3 or a number of related analogs prior to onset of diabetes can considerably reduce the subsequent development of pancreatic islet immune infiltration (insulitis) and overt diabetes without inducing broad immunosuppression (85) . This finding has been recently confirmed by Gregori et al. using a nonhypercalcemic 1,25(OH) 2 D 3 analog (53). Bouillon and colleagues have also examined the therapeutic efficacy of 1,25(OH) 2 D 3 agonists administered after the development of insulitis and in diabetic NOD mice receiving syngeneic islet transplants in whom recurrent autoimmunity is invariable (37, 39) . The reported results suggest that introduction of a 1,25(OH) 2 D 3 analog in animals with an established autoimmune process exerts only a minor effect on islet destruction. In contrast, the combination of a 1,25(OH) 2 D 3 analog with additional immunomodulatory agents (cyclosporine or interferon β) could significantly retard the progression or recurrence of the autoimmune response to insulin-producing cells (37, 39, 57) . This same group, as well as that of Adorini, has examined a number of the mechanistic aspects of 1,25(OH) 2 D 3 -mediated protection against autoimmune diabetes in NOD mice (36, 38, 53, 97) . These studies reveal a complexity that is unlikely to be explained by a single cellular target or inhibitory mechanism. Included among the important observations from these investigations is evidence for in vivo suppression of Th-1 T-cell responses, a permissive effect on autoantigen-specific Th-2 T-cell responses, development of autoantigen-specific regulatory T-cells, and restoration of activation-or drug-induced apoptosis in thymocytes and effector T-cells from NOD mice. Combined influences of 1,25(OH) 2 D 3 agonists on APCs and activated T-cells are likely to underlie such observations. 2) Induced Immune-mediated Disease: Many animal models of induced autoimmunity and immune-mediated tissue injury have been developed with variable degrees of similarity to human diseases. In contrast to the genetically based models, these induced models provide an opportunity to study the efficacy of therapeutic intervention at precisely defined points during a disease process in previously healthy adult animals. (24) and sirolimus (rapamycin) (23) . The mechanism of action of 1,25(OH) 2 D 3 in EAE has been the subject of a number of studies by these same groups although in some respects the results have been inconsistent. Evidence for a deviation toward a Th-2 T-cell response to MBP has been presented by Cantorna 3) Transplantation: The success of organ and cellular transplantation is highly dependent on the use of immune suppression, and animal models of transplantation represent an essential testing ground for novel immunosuppressive agents. Major goals in the advancement of transplantation medicine include the reduction of long-term toxicity associated with immunosuppressive regimens and the identification of agents that promote immune tolerance to grafted tissues without compromising overall protective immunity. For both of these goals there is evidence that 1,25(OH) 2 D 3 agonists may be of significant benefit in posttransplant immunosuppression. The efficacy and toxicity of 1,25(OH) 2 D 3 and related analogs has been studied in a variety of mouse and rat transplant models including skin (134) , heart (61, 65, 77) , kidney (108), intestine (65), liver (109), pancreatic islets (52), and aorta (106) . As monotherapy, these agents have typically been shown to result in significant but modest prolongation of graft function. More strikingly, the combination of a 1,25(OH) 2 D 3 agonist with cyclosporine or mycophenolate mofetilboth immunosuppressants in common clinical use for transplantation-has been observed to result in prolonged graft survival compared with either agent alone (52, 108, 134 
In Vitro Versus In Vivo Potency
The systemic bioavailability of 1,25(OH) 2 D 3 in vivo is dependent on its overall concentration in the serum and, perhaps, on the concentration of vitamin D-binding protein (DBP) (21, 66) . The magnitude of its effect upon a target tissue is, furthermore, dependent on intracellular levels of vitamin D receptor (VDR), on the concomitant expression of additional members of the DNA-binding complex such as retinoic X receptor (RXR), and on the rate of conversion of 1,25(OH) 2 D 3 to inactive metabolites (21, 35, 66) . Analogs of 1,25(OH) 2 D 3 may differ considerably from the parent compound in bioavailability and target tissue potency on the basis of alterations in affinity for DBP, alterations in susceptibility to degradation, and alterations in affinity for or conformational modification of the VDR (20) . These in vivo complexities should be appreciated when interpreting 1,25(OH) 2 D 3 -and 1,25(OH) 2 D 3 analog-mediated effects in in vitro culture systems. Although the presence of serum in most culture systems represents a source of DBP, concentrations may vary considerably. In addition, the induction of degrading enzymes in cultured cells may not mimic that to be encountered in whole organs or tissues in vivo.
As demonstrated by Bouillon (20) , analogs with low affinity for DBP may demonstrate enhanced in vitro potency compared to 1,25(OH) 2 D 3 but may prove significantly less potent in vivo if subject to rapid intracellular metabolism. The combination of partial DBP affinity, attenuated susceptibility to metabolic inactivation, and preserved affinity for VDR would appear to identify analogs with high in vivo potency. For the purpose of human immunotherapy, however, a 1,25(OH) 2 D 3 analog must demonstrate a further distinction from the parent compound-a separation between in vivo immunomodulatory and hypercalcemic potency.
Hypercalcemia
The primary toxicity of 1,25(OH) 2 D 3 is the induction of hypercalcemia as a result of enhanced intestinal absorption and bone calcium mobilization (66) . It is clear from many studies involving animal models of immune-mediated disease that the efficacy of 1,25(OH) 2 D 3 therapy is limited by the occurrence of hypercalcemia with increased or prolonged dosage (79, 80, 138) . The capacity for various 1,25(OH) 2 D 3 analogs to induce hypercalcemia or to reduce bone calcium content has been studied by many groups. Although it is likely that all 1,25(OH) 2 D 3 analogs retain the tendency to increase serum calcium if administered at sufficient doses (22, 77, 80, 134, 138) , it is clear from a number of recent studies that some immunomodulatory analogs are many-fold less potent in this regard than the parent compound (2, 18, 21, 37, 53, 57, 78, 142, 143) . The mechanistic basis for this reduced hypercalcemic effect has not been completely elucidated but it is possible that, in addition to possessing modifications that favor high intracellular accumulation, such analogs induce conformational changes in the VDR that alter the structural and functional properties of the entire DNA-binding complex (133) . In this way it has been proposed that 1,25(OH) 2 D 3 analogs, when bound to VDR, are responsible for modified gene expression profiles compared to the physiologic 1,25(OH) 2 D 3 /VDR complex (35, 133) . Further characterization of the molecular events underlying the separation of hypercalcemic and nonhypercalcemic effects of 1,25(OH) 2 D 3 agonists may allow for the development of even more selective analogs as immunotherapeutic agents.
Timing and Duration of Therapy
The optimal timing and duration of therapy with 1,25(OH) 2 D 3 or 1,25(OH) 2 D 3 analogs should be carefully examined when evaluating the potential for translating experimental results into human clinical trials. Some of the in vivo studies in which 1,25(OH) 2 D 3 or related analogs were found to favorably alter immune responses report relatively narrow therapeutic dose ranges (2, 53, 75, 79) . In some studies, small variations in dosage or dose frequency were found to be associated with loss of efficacy or emergence of toxicity (53, 75, 79) . In others, loss of efficacy was observed with dose levels both above and below the optimal dose (2). It is interesting to compare these observations with a number of in vitro phenomena in which the titration of 1,25(OH) 2 D 3 agonists across a range of concentrations has resulted in biphasic responses (54, 112) . An implication of these results is that careful preclinical studies must be carried for 1,25(OH) 2 D 3 analogs to identify dosages with both minimal toxicity and optimal immunomodulatory effects.
In general, initiation of 1,25(OH) 2 D 3 therapy prior to or coincident with the induction of disease has been associated with the most striking beneficial effects for models of immune-mediated diseases. Furthermore, disease progression or relapse has been observed when therapy has been withdrawn (29) . This implies that the clinical use of 1,25(OH) 2 D 3 agonists could be best applied to disease prevention (such as in transplantation or prediabetic patients) or the maintenance of remission in relapsing conditions (such as multiple sclerosis). There are, however, examples of models in which significant improvements in an established autoimmune process have been reported. In these experiments, higher doses and additional manipulations to avoid hypercalcemia have been required (29, 30) . These observations suggest that 1,25(OH) 2 D 3 analogs with reduced toxicity may also prove to be effective, either alone or in combination with other immunomodulatory agents (37, 39) , in managing active immune diseases. Although the majority of animal studies in which duration of therapy has been examined suggest that continuous, long-term therapy with a 1,25(OH) 2 D 3 agonist will be required to prevent disease relapse, Adorini's group has observed long-lived protection against islet allograft rejection and autoimmune diabetes following limited courses of therapy (52, 53) . These experiments raise the possibility that manipulation of the immune system by 1,25(OH) 2 D 3 may favor the emergence of persistent immune regulatory mechanisms.
Combined Effects With Other Immunomodulatory Agents
The effect of combining 1,25(OH) 2 D 3 or related analogs with other immunomodulatory agents has been referred to repeatedly in preceding sections and many studies have confirmed additive or synergistic effects in vitro and in vivo using such combinations. Among the clinically relevant agents that have been reported to enhance the immunosuppressive effects of 1,25(OH) 2 D 3 agonists are corticosteroids (14, 64, 69, 136) , the calcineurin inhibitors cyclosporine and tacrolimus (24, 37, 48, 80, 108, 129, 134) , the cell cycle inhibitor sirolimus (23, 129) , the antiproliferative agents mycophenolate mofetil (52, 129) and leflunamide (129) , and the cytokine interferon-β (57). In the case of corticosteroids, we have recently reported a potent additive effect of a 1,25(OH) 2 D 3 analog with dexamethasone on the ability of DCs to stimulate T-cell activation (136) . This finding is demonstrated in Figure 4 . As shown, the ability of bone marrow-derived DCs to potently stimulate the proliferation of antigen-specific CD4+ T-cells is significantly inhibited by generation of the DCs in the presence of 1,25(OH) 2 D 3 or corticosteroid agonists alone and is virtually abolished by the combined effects of the two steroid hormone pathways. In a detailed analysis, Van Etten et al. (129) have directly compared the synergism between 1,25(OH) 2 be designed to both enhance the efficacy and reduce the toxicity of each agent.
Dietary Influences
A final consideration in optimizing the effectiveness of 1,25(OH) 2 D 3 analogs in immune-mediated diseases has been raised by the observations of DeLuca and Cantorna on the role of dietary calcium content in a number of murine models (32, 46) . These authors have reported that the beneficial effects of 1,25(OH) 2 D 3 in EAE-and SLE-prone mice are significantly attenuated by a low calcium intake. Interestingly, the induction of hypercalcemia during 1,25(OH) 2 D 3 therapy did not restore therapeutic efficacy in animals on low calcium diets. Although the mechanism underlying such an effect is unclear, the results suggest that restriction of dietary calcium in patients receiving 1,25(OH) 2 D 3 analogs may actually limit therapeutic efficacy.
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TOWARD AN UNDERSTANDING OF THE PHYSIOLOGIC ROLES OF VITAMIN D IN IMMUNE FUNCTION
The extensive literature documenting specific effects of 1,25(OH) 2 D 3 on macrophages, DCs, and T-cells provides strong evidence of a true physiologic role for this steroid pathway in normal immune function. The ability of some or all of these cell types to produce 1,25(OH) 2 D 3 under some conditions suggests, furthermore, a paracrine model in which appropriate stimuli induce immunomodulatory concentrations of 1,25(OH) 2 D 3 within the microenvironment of an inflamed tissue or lymphoid organ (4, 8, 26, 94 (87, 92) . This form of immunity is typically associated with locally destructive lymphocytic infiltration, is stimulated by DCs presenting antigen in the presence of the cytokine IL-12, and is characterized by the production of high levels of interferon-γ (71). Inhibition of factors leading to Th-1 polarization following activation of innate responses is likely to be important for the avoidance of autoimmunity. A number of lines of evidence point to a significant role for 1,25(OH) 2 D 3 in the negative regulation of Th-1-type immunity (76) . These include the documented effect of 1,25(OH) 2 D 3 to specifically inhibit DC maturation and production of IL-12 (54, 55, 99, 100, 130) and to directly regulate interferon-γ gene transcription (43, 110, 113) . Direct inhibition of IL-2 production and activated T-cell proliferation by 1,25(OH) 2 D 3 likely also contributes to the regulation of Th-1 responses through the limitation of clonal expansion and CD4+ T-cell help to cytotoxic (CD8+) T-cells (12 (9, 19, 34, 52, 53) . It remains to be determined, however, whether these phenomena are the result of preferential suppression of Th-1 responses or represent specific stimulation of alternative T-helper differentiation programs. It is also unclear whether such effects are mediated through modification of DC maturity, through direct effects on T-cells, or, as now seems likely, through a combination of the two. It may be possible to address such questions by further study of animals unresponsive to 1,25(OH) 2 D 3 through knockout of the gene for VDR. Preliminary studies of the immune system of such VDR-deficient mice has demonstrated hypertrophy of subcutaneous lymph nodes with an increased proportion of highly mature DCs (55) . These animals have not, however, been found to have widespread autoimmunity or intrinsic defects in in vitro lymphocyte function (86) . A better appreciation of the physiological role of 1,25(OH) 2 D 3 in the regulation of immune tolerance and T-helper phenotype may require the generation of in vivo systems in which VDR-deficient immune populations are observed in otherwise normal hosts.
CONCLUSIONS
The studies reviewed here establish important effects of 1,25(OH) 2 D 3 on normal and abnormal immune function. The therapeutic application of these insights is currently in its infancy but the availability of 1,25(OH) 2 D 3 analogs with favorable in vivo profiles has been well documented and it is likely that clinical trials will demonstrate significant beneficial effects for such agents in autoimmune disease and transplantation. As conceptual models of immune system regulation continue to develop it is also likely that important physiological roles for the observed influences of 1,25(OH) 2 D 3 on multiple immune cell types will be identified. 
